DOXAZOSIN MESYLATE

Search structure


Trade Names:	CARDURA CARDURA XL DOXAZOSIN MESYLATE
Synonyms:	Alfadil Cardozin xl Cardura Cardura xl Cascor Colixil xl Doxadura Doxazosin (as mesilate) Doxazosin mesilate Doxazosin mesylate Doxazosin methanesulfonate Doxzogen xl Larbex xl NSC-759284 Oxandosin xl Raporsin xl Slocinx xl UK-33,274-27 UK-33274-27
Status:	Approved (1990)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	86P6PQK0MU
Parent Compound:	DOXAZOSIN

Structure


InChI Key	VJECBOKJABCYMF-UHFFFAOYSA-N
Smile	COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O
InChI	InChI=1S/C23H25N5O5.CH4O3S/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20;1-5(2,3)4/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26);1H3,(H,2,3,4)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H29N5O8S
Molecular Weight	547.59
AlogP	1.72
Hydrogen Bond Acceptor	9.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	112.27
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	33.0

Pharmacology

Action	Mechanism of Action	Reference
ANTAGONIST	Adrenergic receptor alpha-1 antagonist	DailyMed Wikipedia

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	-	-	-	5
Surface antigen	-	-	15700	-	-
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	45000	-	-	-
Transporter Primary active transporter ATP-binding cassette ABCC subfamily	-	8000	-	-	-

Metabolites

visNetwork

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Hypertension	4	D006973	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Nervous system disorders	13.41
General disorders and administration site conditions	11.48
Vascular disorders	11.42
Cardiac disorders	11.03
Gastrointestinal disorders	6.0
Respiratory, thoracic and mediastinal disorders	5.97
Renal and urinary disorders	5.4
Musculoskeletal and connective tissue disorders	4.71
Psychiatric disorders	4.63
Investigations	4.37
Skin and subcutaneous tissue disorders	4.31
Injury, poisoning and procedural complications	3.44
Metabolism and nutrition disorders	2.97
Immune system disorders	2.82

Cross References

Resources	Reference
ChEBI	4709
ChEMBL	CHEMBL1200561
EPA CompTox	DTXSID5045598
FDA SRS	86P6PQK0MU
Guide to Pharmacology	7170
KEGG	C06970
PubChem	62978
SureChEMBL	SCHEMBL42621
ZINC	ZINC00896512

CONTENTS